ArticleApplied biochemistry and biotechnology2026
NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cordyceps as a multitarget therapeutic platform: biology, bioactive metabolites, and translational challenges.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNucleolar complex associated 4 homolog (NOC4L) is implicated in the pathogenesis of various diseases and has been reported to play a role in tumorigenesis. However, its diagnostic and prognostic significance across diverse cancer types remains underexplored.
methodsThis study employed bioinformatics methodologies to analyze NOC4L expression across diverse cancers using public databases, including The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) project. Comprehensive analyses, including survival analysis, receiver operating characteristic (ROC) curves, and functional enrichment studies, were performed to assess the clinical significance of NOC4L expression.
resultsNOC4L mRNA expression was significantly elevated in multiple cancers, with notable upregulation observed in bladder (BLCA), breast (BRCA), and colon (COAD) cancers, showing significant differences when compared to adjacent normal tissues. Kaplan-Meier survival analysis indicated that NOC4L expression is associated with overall survival in 20 cancer types, suggesting its potential as an independent prognostic marker. Additionally, variation in NOC4L expression among different immune subtypes points to its role in modulating the tumor immune microenvironment. Protein-protein interaction network analysis identified key proteins associated with cancer prognosis. Gene Ontology and KEGG pathway analyses revealed that NOC4L-related genes are involved in critical cancer-related pathways, including ribosome biogenesis, cell cycle regulation, and DNA damage response.
conclusionsNOC4L shows promise as a dual-action target, functioning both as a prognostic biomarker and as a potential immunotherapeutic target. These insights provide a foundation for future research into its potential therapeutic applications.
Indexed as
Identifiers
42776443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.